Pfizer看多
PFE set for a rebound
已更新
PFE beat analysts' estimates on EPS but provided an outlook that didn`t meet expectations. However, The Co expects revenues to grow by 7-9% in 2023. Considering its plans to boost business by acquiring SGEN, the current market cap looks attractive as a reverse to mean play and a fundamentally driven long-term investment case.
交易結束：達到停損點
Stop reached, if the price goes again above 41 I will be a buyer.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。